Bio News
The FDA approved Merck’s oral PCSK9 inhibitor Lipendra as the representative for the CNPV pilot program based on its 60% reduction in LDL-C. Merck said Lipendra lowered LDL-C by approximately 60% at week 24 in clinical trials. Merck plans to expand penetration in the PCSK9 market, which has reached only 5% of 30 million people, with Lipendra priced at $315 per month (450,000 won).
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
